Hims & Hers stock rallies

The rally in Hims & Hers stock reflects investor optimism that the administration's new health policies will create lucrative opportunities for compounding pharmacies.

Kennedy has publicly touted the benefits of certain peptides for weight loss and anti-aging, despite a lack of new safety data.

Analysts suggest that a successful regulatory overhaul could significantly boost the company's revenue as it looks beyond its core GLP-1 business.

The potential policy shift is part of a broader effort by the Trump administration to reform the FDA and promote alternative medical treatments.